Add-on Studies / Sequential Design [Design Issues]

posted by joyjac – Philippines, 2006-07-19 07:10 (6285 d 12:25 ago) – Posting: # 179
Views: 10,867

I have some questions regarding add-on studies /sequential design.
  1. Are these acceptable in bioequivalence studies if specified a priori in the protocol? Would you know if US FDA, EMEA, Canada, ASEAN accept such design?
  2. When an add-on study is conducted (and combined with the original study), what would be the statistical method of analysis?
  3. Can we still apply the 90% Confidence Interval criteria for bioequivalence or would it have to be more restrictive i.e. 95% CI?
  4. Could the first study be discarded if the second study passed the 90% CI BE criteria on its own?
  5. More importantly, what are its pros and cons with regards to consumer protection or risk.
Thank you so much for the knowledge sharing.

Complete thread:

UA Flag
 Admin contact
22,771 posts in 4,777 threads, 1,627 registered users;
13 visitors (1 registered, 12 guests [including 7 identified bots]).
Forum time: 19:35 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz